Moteur de recherche d’entreprises européennes
Financement de l’UE (7 430 427 €) : Définition des phénotypes cliniques et moléculaires de la multirésistance aux médicaments dans la polyarthrite rhumatoïde difficile à traiter Hor12/12/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Définition des phénotypes cliniques et moléculaires de la multirésistance aux médicaments dans la polyarthrite rhumatoïde difficile à traiter
Rheumatoid Arthritis (RA) is the most common, chronic, inflammatory joint disease with a prevalence of about 1% of the adult population (22M patients worldwide and 7M in EU) and estimated to be responsible for 10,000 disability adjusted life years (DALY's) costing EU society €55B annually. Despite aggressive therapy, about a third of patients have to give up work within 5 years of disease onset mainly due to lack of response to multiple disease modifying anti-rheumatic drugs (DMARDs), multi-drug resistance (MDR). Thus, the main objective of this proposal is to define the clinical and molecular phenotypes leading to MDR in RA patients to prevent when possible or, when not possible, optimise the management of these patients. MDR-RA is highly relevant to the program, as these patients are often disabled, unable to work and paying a high personal and societal burden. Moreover, MDR-RA is under-researched and the underlying pathobiological mechanisms for resistance remain unknown, while as we have no predictors of therapeutic response to any of currently available drugs, inevitably treatment is based on trial-and-error. MDR-RA has the ambition of transforming care for these patients and deliver significant advances beyond the state-of-the-art methodologies, as for the first time, molecular pathology will be integrated into clinical, psychosocial, pain perception and imaging profiling in existing clinical cohorts to develop truly holistic predictive models for future clinical use (iCare-RA). The transformative potential of iCare-RA will be tested in a prospective randomised trial in comparison with routine standard of care, while its future implementation potential will be assessed through an early economic modelling. Finally, a strong management and dissemination strategy will facilitate further advancing science in the field, beyond the duration of the project, and future adoption by patients, specialist professional bodies, policy makers and regulatory authorities.
| AARDEX GROUP SA | ? |
| Cliniques Universitaires Saint-LUC ASBL | 213 000 € |
| Diakonhjemmet Sykehus AS | 315 022 € |
| Eutema Research Services GmbH | 369 125 € |
| Fundacao Gimm - Gulbenkian Institute For Molecular Medicine | 143 762 € |
| Fundacion para La Investigacion Biomedica de Cordoba | 0,00 € |
| Humanitas Mirasole S.p.A. | 0,00 € |
| Instituto de Salud Musculoesqueletica SL | 125 641 € |
| Karolinska Institutet | 144 135 € |
| Medizinische Universitaet Wien | 287 906 € |
| Pluribus ONE Srl | 180 125 € |
| Queen Mary University of London | 1 213 195 € |
| Region Stockholm | 103 012 € |
| Region Syddanmark | 178 381 € |
| Servicio Andaluz de Salud | 199 062 € |
| The University of Manchester | 441 968 € |
| Universita Cattolica Del Sacro Cuore | 350 100 € |
| Universita Degli Studi Di Verona | 490 750 € |
| Universita Humanitas | 2 153 088 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | 206 837 € |
| UNIVERSITATSKLINIKUM ERLANGEN | 315 318 € |
https://cordis.europa.eu/project/id/101155807
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Aardex Group SA, Sion, Suisse.
